Orticumab
Product Specifications
UNSPSC Description
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].
Target Antigen
LDLR
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/orticumab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Orticumab]
References & Citations
[1]Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. |[2]Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99793/Orticumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99793/Orticumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1314241-10-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
